This activity is supported by independent educational grants from AstraZeneca, Pfizer, and Takeda Oncology.
Advances in the Use of Targeted Therapies in the Management of Non–Small Cell Lung Cancer
Heather Wakelee, MD
Stanford Health Care
Elizabeth S. Waxman, RN, MSN, AOCN®, ANP-BC
The University of Texas MD Anderson Cancer Center
Learn about the recent updates in the world of genetic testing and targeted therapies for non–small cell lung cancer. It’s vital that advanced practitioners in oncology have the latest knowledge on EGFR, ALK, and BRAF inhibitors, as well as acquired resistance mutations, to help patients from diagnosis through treatment.
These CME/CE/CPE accredited activities are jointly provided by